Florian L.
- Country
- Germany
- Department
- Universitäres Krebszentrum Leipzig (UCCL)
Research Overview
- Efficacy and Safety of PF-08634404 and Combination Therapy Versus Bevacizumab and Combination Therapy in Treatment-Naïve Participants With Metastatic Colorectal Cancer
- Volrustomig Monotherapy or Combination Chemotherapy in Advanced Solid Tumors: Phase II Study in Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma
- Phase III Randomized Trial of AZD0901 with Capecitabine ± Rilvegostomig in First‑Line Claudin‑18.2‑Positive HER2‑Negative Advanced Gastric, GEJ or Esophageal Adenocarcinoma
Data & Insights
Has run more than one trial at 146 of 302 partner sites.
Specializations
Gastrointestinal Oncology
Specializes in treating advanced forms of esophageal, gastric, and gastroesophageal junction cancers, with particular focus on adenocarcinomas and squamous cell carcinomas.
- HER2-positive gastric cancers
- Metastatic esophagogastric adenocarcinoma
- Unresectable esophageal malignancies
Investigates innovative therapeutic approaches for locally advanced and metastatic gastrointestinal malignancies.
Targeted Therapies
Focuses on novel targeted treatments including antibody-drug conjugates and HER2-directed therapies across multiple tumor types.
- TROP-2 targeting antibodies
- HER2-mutation targeted approaches
- Combination immunotherapy strategies
Develops personalized treatment approaches based on specific molecular markers and genetic alterations.
Multi-Cancer Research
Conducts research across various solid tumor types including breast cancer, head and neck cancer, and hepatocellular carcinoma.
- Pan-tumor therapeutic approaches
- Advanced metastatic disease
- Neoadjuvant treatment strategies
Evaluates novel therapeutic combinations for patients with recurrent or metastatic solid tumors.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.